On September 5, 2018 Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, reported its award of a $300,000 (USD) grant from the National Cancer Institute of the National Institutes of Health (NIH) (Press release, Zetagen Therapeutics, SEP 5, 2018, View Source [SID1234643681]). The grant will be used for a Phase I validation study of the Company’s proprietary, drug-eluding implant called ZetaMet (Zeta-BC-003). ZetaMet (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic being developed to suspend tumor growth and regrow bone.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that the National Cancer Institute, through this award, has recognized the potential ZetaMet (Zeta-BC-003) may hold for treating metastatic bone lesions," said Nikhil Thakur, MD, CMO of Zetagen Therapeutics, Inc. "Osteolytic metastases are among the most challenging of cancers to treat as they both destroy bone and cause debilitating pain in patients."

The grant is part of the Small Business Innovation Research Program (SBIR), a three-phase award system created by the Federal Government for small businesses to engage in research and development that has the potential for commercialization and public benefit. Zetagen exclusively licensed its platform technology from the State University of New York in 2016. The Company’s Phase I validation study will begin in Q4 2018.

On September 5, 2018 Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, reported that company management will participate in a fireside chat at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 1:40 p.m. ET (Press release, Blueprint Medicines, SEPT 5, 2018, View Source [SID1234529289]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On September 5, 2018 Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that the planned second interim analysis of the Oraxol 001 Phase III Clinical Trial in metastatic breast cancer has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB) (Press release, Athenex, SEP 5, 2018, View Source;p=RssLanding&cat=news&id=2366074 [SID1234529329]). The DSMB congratulated Athenex on the rapid patient recruitment and the promising results achieved. The DSMB noted that more than 320 patients have already been recruited and recommended that Athenex continue this study and complete the recruitment of patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Oraxol 001 Phase III Clinical Trial is a randomized controlled clinical trial comparing Oraxol monotherapy against intravenous (IV) paclitaxel monotherapy in patients with metastatic breast cancer. The study is designed to compare the safety and demonstrate the superiority of Oraxol over IV paclitaxel. Clinical activity is based on confirmed response rate as assessed by RECIST Criteria, a generally accepted clinical response criteria for efficacy in tumor reduction. Assessment of tumors scans are made by a blinded independent radiologic imaging analysis center.

Dr. Rudolf Kwan, Athenex’s Chief Medical Officer, commented, "After review of the efficacy and safety data of this Oraxol Phase III clinical trial, the unanimous recommendation by the DSMB to continue this study represents the achievement of another critical milestone for Oraxol. We plan to provide these confidential unblinded data to regulatory authorities soon to discuss the marketing submission pathways. In the mean time, we will continue to rapidly advance this clinical trial."

Dr. Johnson Lau, Athenex’s Chairman of the Board and Chief Executive Officer, stated, "The positive recommendation of the DSMB regarding the Oraxol Phase III study in patients with metastatic breast cancer, in combination with the successful completion of two Phase III clinical studies for KX-01 for Actinic Keratosis ahead of schedule as previously announced on July 26, 2018, together underscore the excellent execution by our clinical research and development team."

On September 5, 2018 Cytokinetics, Inc. (Nasdaq: CYTK) reported that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM ET at the Grant Hyatt in New York City (Press release, Cytokinetics, SEPT 5, 2018, View Source [SID1234529290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.

On September 5, 2018 Exelixis, Inc. (NASDAQ: EXEL) reported that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Morgan Stanley Global Health Care Conference taking place September 12-14 in New York, NY (Press release, Exelixis, SEPT 5, 2018, View Source;p=irol-newsArticle&ID=2366220 [SID1234529291]). The Exelixis presentation is scheduled for 1:05 PM EDT / 10:05 AM PDT on Wednesday, September 12, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.